Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
We being me as a private shareholder and Ananda the company I'm invested in!
Get a life and do one before making wrong calls on a public chat site!
I'm not connected in anyway to the company other than a private investor so I suggest you delete that quote before I take action against you!
Admin please
We were half way through our stabilisation production when it made economic and timing sense to pause but now we are looking to proceed working with the program with Nottingham Trent university and it's 3rd party funding so the moved has had a very positive outcome as we await commencement news to kick start where we left off
A key focus for Ananda is developing the evidence required to prove the efficacy of its cannabinoid medicines, and we are motivated by the calls of UK regulators for evidence to unlock NHS funding.
MRX Medical is providing one of its cannabidiol formulations, MRX1, into two Phase II clinical trials that have received a combined £1.55 million in non-dilutive funding.
One of the clinical trials will use one of our formulations to target the treatment of Chemotherapy Induced Peripheral Neuropathy (CIPN), which approximately 160,000 people in the UK are diagnosed with each year. The other trial will use the same formulation to target the treatment of the pain associated with endometriosis, which is suffered by 1.5 million women in the UK.
In addition to these funded trials, Ananda continues to develop a pipeline of opportunities to further build evidence through clinical trials.
Despite very strict cannabis regulations in Japan, some cannabidiol (CBD) products have been legally distributed since 2013 and taken by some patients with epilepsy.
A self-administered questionnaire was sent to 38 patients with intractable epilepsy who were taking CBD
The median CBD intake was 12.0 mg/kg/day NB: Product was CBD isolate.
Fifteen patients (53.6%) reported a decrease in seizure frequency. Moreover, two patients (7.1%) showed complete resolution of seizures.
No significant correlation was found between the patient’s diagnosis and seizure type or treatment efficacy.
Conclusions: This is the first cross-sectional study of CBD users in Japan suggesting that CBD may be an effective option for Asian patients with refractory epilepsy, regardless of diagnosis or seizure type.
5. Innovation in Healthcare: With an open policy, the UK could become a leader in cannabis-based treatment innovation, attracting researchers, pharmaceutical companies, & investors interested in developing new therapeutic products. This could lead to the creation of novel drug formulations & delivery systems, further expanding treatment options for patients.
Https://twitter.com/Share_Talk/status/1762809896112992478?t=pTWBoYnYbTvXTogPoGrNqg&s=19
I see the Bod fully committed on personal multi million funds within this company and working hard to align multiple rcts to fulfill guidance set out by governing bodies to prove pain relief is controlled within different conditions by real data collected which will be better all round for patients and The NHS on its current spend with out success! Timing is every and perhaps your buys time wise weren't the best! As for the temporary haul on the grow facility at mid stage, this turns out to be a masterclass as we are now going to continue on 3rd party funding instead of our own! Pretty smart business model all round I'd say on the stabilisation side and rct's whilst retaining all ip and commercial rights!